Inactive

INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The Nat... INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Office of Acquisitions (OA) on behalf of the on behalf of the National Institute of Digestive, Diabetes & Kidney Diseases intends to award a purchase order without providing for full and open competition (Including brand-name) to 10X GENOMICS, INC for the purchase of Chromium Single Cell Human BCR Amplification Kit, 16 rxns and associated reagents. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 325180 with a Size Standard of 1,000. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2021-05 effective March 10, 2021. This acquisition is conducted under the procedures as prescribed in FAR subpart 13—Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($250,000). STATUTORY AUTHORITY This acquisition is conducted under the authority of 41 U.S.C. 253(c) under provisions of the statutory authority of FAR Subpart 6.302- FAR 6.302-1—Only one responsible source and no other supplies or services will satisfy agency requirements 41 U.S.C. 253(c)(1). PERIOD OF PERFORMANCE Within 90 Days of Award Place of Performance National Institutes of Health National Institute of Digestive, Diabetes & Kidney Diseases 5 Memorial Drive Bethesda MD 20892 ? DESCRIPTION OF REQUIREMENT The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) conducts and supports research on many of the most serious diseases affecting public health. The Institute supports much of the clinical research on the diseases of internal medicine and related subspecialty fields, as well as many basic science disciplines. The Institute's Division of Intramural Research encompasses the broad spectrum of metabolic diseases such as diabetes, obesity, inborn errors of metabolism, endocrine disorders, mineral metabolism, digestive and liver diseases, nutrition, urology and renal disease, and hematology. Basic research studies include biochemistry, biophysics, nutrition, pathology, histochemistry, bioorganic chemistry, physical chemistry, chemical and molecular biology, and pharmacology. NIDDK extramural research is organized into 4 divisions: Diabetes, Endocrinology, and Metabolic Diseases; Digestive Diseases and Nutrition; Kidney, Urologic, and Hematologic Diseases; and Extramural Activities. The Institute supports basic and clinical research through investigator-initiated grants, program project and center grants, and career development and training awards. The Institute also supports research and development projects and large-scale clinical trials through contracts. _________________________ The liver responds to immune signals and infiltrating cells from the gut and the spleen delivered through the portal vein. However, the contents of the portal vein are not well characterized, especially across liver disease severity. Hepatitis C can be used as a model for understanding liver disease beyond viral infection because patients can clear the infection yet still have underlying fibrosis and portal hypertension. As a collaboration with Dr. John O’Shea’s lab in NIAMS, a pilot experiment examined immune cells at a single-cell resolution from portal and peripheral blood samples collected from two non-cirrhotic patients who cleared HCV. The results suggested that hepatic portal blood contained unique subsets of circulating immune cells not present in peripheral blood. We believe that the presence of unique populations of activated and exhausted circulating immune cells in portal vein blood potentially suggests a role for the gut and spleen in the activation of immune cells before reaching the liver. As a follow-up experiment, we repeated the workflow with portal, peripheral, and splenic samples from six additional patients across the fibrosis spectrum. TCR sequencing, BCR sequencing, and CITE-seq were also performed. We are now interested in repeating the experiments with samples collected from these same eight patients while they were still infected with HCV. We have used the Chromium Single Cell Gene Expression platform from 10X Genomics to perform the experiments thus far, and 10X Genomics distributes their proprietary reagents for their instrument (the Chromium Controller). Their platform is the best for doing these types of integrative experiments and analyses. Thus, we require the appropriate reagents to continue the work performed on this instrument in collaboration with NIAMS. PURPOSE AND OBJECTIVES The National Institutes of Health (NIH)’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has a requirement for reagents to continue the research work performed on the Chromium Controller instrument in collaboration with NIAMS. SALIENT / REQUIRED FEATURES AND SPECIFICATIONS Independently, and not as an agent of the Government, the contractor shall provide the following: • Chromium Single Cell Human BCR Amplification Kit, 16 rxns • Chromium Single Cell Human TCR Amplification Kit, 16 rxns • Chromium Next GEM Chip K Single Cell Kit, 16 rxns • 5' Feature Barcode Kit, 16 rxns • Dual Index Kit TN Set A, 96 rxn • Library Construction Kit, 16 rxns • Chromium Next GEM Single Cell 5' Kit v2, 16 rxns TASKS AREAS Specifically, the NIDDK requires the following tasks: Task Area 1 – Delivery time will be no more than 60 Days of award of the Purchase Order (PO). Task Area 2 – The reagents will be shipped by the manufacturer in containers that ensure the reagents remain at their recommended temperatures while in shipment.. CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted as prescribed in FAR Part 10—Market Research. Only one source is available: Per FAR 13.106-1(b)(1) the Contracting Officer has determined 10X GENOMICS, INC. to be the only reasonable available source to provide 10X GENOMICS proprietary reagents. This acquisition was pursued on a sole source basis centered on the NIDDK having used the Chromium Single Cell Gene Expression platform from 10X Genomics to perform the requisite experiments so far. In addition, 10X Genomics distributes their proprietary reagents for their machine (the Chromium Controller) providing ultimate compatibility for these types of integrative experiments and analyses. Moreover, the NIDDK requires 10X GENOMICS, INC’S reagents in order to continue the work performed on this instrument in collaboration with NIAMS. Failure to procure these reagents from 10X GENOMICS, INC. would result in a significant loss of research. 10X GENOMICS, INC. is the sole supplier of the Chromium Single Cell Expression platform and the proprietary reagents it requires in order to function. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: descriptive literature, delivery timeframe, warranties and/or other information that demonstrates that the offer meets all the foregoing requirements, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.” A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses to this notice shall be submitted electronically by 9:00 am Eastern Standard Time, on Tuesday, June 8, 2021 to the Contracting Officer, Amber Harris, at amber.harris@nih.gov. Assessment of Capability Lowest Price Technically Acceptable